Immunomedics, Inc. has received $-0.13 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.15 while the top line estimate is $-0.11 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 13.33%.
Immunomedics, Inc. results fell short with a surprise EPS of -41.67% or $-0.05. The Actual EPS was $-0.17 compared to the Estimated EPS of $-0.12 during its most recent quarterly earnings.
In the last quarter, Immunomedics, Inc. reported Annual Earnings of $-0.17. Based on the filings, last years Annual Earnings was, $-0.62. In the last Quarter, IMMU reported a surprise Earnings per Share of -41.67% . The consensus estimate for current quarter is $-0.13 and for the current fiscal year, the estimate is $-0.51. For the Next fiscal year, the estimate is $-0.23 based on the consensus.
Immunomedics, Inc. (NASDAQ:IMMU) : On Tuesday heightened volatility was witnessed in Immunomedics, Inc. (NASDAQ:IMMU) which led to swings in the share price. The stock opened for trading at $4.45 and hit $4.54 on the upside , eventually ending the session at $4.5, with a gain of 1.35% or 0.06 points. The heightened volatility saw the trading volume jump to 2,512,113 shares. The 52-week high of the share price is $5.44 and the company has a market cap of $477 million. The 52-week low of the share price is at $1.61 .
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.